Comments on Immunogenicity Associated with Botulinum Toxin Treatment. <i>Toxins</i> 2019, <i>11</i>, 491

by Keith Foster, Matthew Beard
Published 2020-01-01

Systematic review of patient and caregivers' satisfaction with telehealth videoconferencing as a mode of service delivery in managing patients' health.

by Joseph F Orlando, Matthew Beard, Saravana Kumar
Published 2019-01-01

The impacts of and outcomes from telehealth delivered in prisons: A systematic review.

by Esther Jie Tian, Sooraj Venugopalan, Saravana Kumar, Matthew Beard
Published 2021-01-01

Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity

by Elena Fonfria, Mark Elliott, Matthew Beard, John A. Chaddock, Johannes Krupp
Published 2018-07-01

Engineering an Effective Human SNAP-23 Cleaving Botulinum Neurotoxin A Variant

by Stefan Sikorra, Sarah Donald, Mark Elliott, Susan Schwede, Shu-Fen Coker, Adam P. Kupinski, Vineeta Tripathi, Keith Foster, Matthew Beard, Thomas Binz
Published 2020-12-01

Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems.

by Mark Elliott, Jacquie Maignel, Sai Man Liu, Christine Favre-Guilmard, Imran Mir, Paul Farrow, Fraser Hornby, Sandra Marlin, Shilpa Palan, Matthew Beard, Johannes Krupp
Published 2017-01-01

Recombinant botulinum neurotoxin serotype A1 in vivo characterization

by Cindy Périer, Vincent Martin, Sylvie Cornet, Christine Favre‐Guilmard, Marie‐Noelle Rocher, Julien Bindler, Stéphanie Wagner, Emile Andriambeloson, Brian Rudkin, Rudy Marty, Alban Vignaud, Matthew Beard, Stephane Lezmi, Mikhail Kalinichev
Published 2021-10-01

Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors

by Liang Tao, Lisheng Peng, Ronnie P.-A. Berntsson, Sai Man Liu, SunHyun Park, Feifan Yu, Christopher Boone, Shilpa Palan, Matthew Beard, Pierre-Etienne Chabrier, Pål Stenmark, Johannes Krupp, Min Dong
Published 2017-07-01